伊沃西登尼布:对先进胆管癌的综述
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.
Targeted oncology
|October 19, 2023
概括
伊沃西迪尼布 (mIDH1抑制剂) 在晚期胆管癌中显著改善了无进展生存率和疾病控制. 这种向治疗也有利地影响了整体生存率和生活质量,证明了它的价值.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胆管癌 (CCA) 是一种具有挑战性的癌症,治疗选择有限.
- 突变异酸盐脱酶1 (mIDH1) 是高级CCA的一个子集中的驱动因素.
- 伊沃西迪尼布向mIDH1,抑制其上代代谢物2 - 氧氨酸.
研究的目的:
- 评估ivosidenib在预先治疗,先进的mIDH1 CCA.患者中的疗效和安全性.
- 评估ivosidenib对无进展生存期 (PFS),总生存期 (OS) 和与健康相关的生活质量 (HRQOL) 的影响.
主要方法:
- 多国,随机,安慰剂控制的,第三阶段ClarIDHy研究.
- 成年患者前期治疗,先进的mIDH1 CCA每天接受ivosidenib或安慰剂.
- 关键的终点包括PFS,OS,客观响应率和HRQOL评估.
主要成果:
- 与安慰剂相比,Ivosidenib显著延长了PFS.
- 随着ivosidenib单独治疗,疾病控制率几乎翻了一番.
- 在OS中观察到有利的趋势,在对交叉进行调整后显著延长.
- 伊沃西代尼布保留了HRQOL,并且通常耐受良好.
结论:
- 伊沃西登尼布是一种针对高级mIDH1 CCA的新型向疗法.
- 它提供了显著的临床益处,包括改善生存率和生活质量.
- 伊沃西登尼布对这种特定患者群体来说是一个有价值的治疗选择.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Chronic Pancreatitis II: Collaborative Care
96
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
96
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Esophageal Varices-II: Clinical Features and Management
73
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
73
